Growing the love for investing
Results 111 - 120 of 359 : Previous 8 9 10 11 12 13 14 15 16 Next
This Just In: Upgrades and Downgrades
Stifel Nicolaus wades back into the biotech sector.
Approval Likely, but Details Still Important
Details will determine the sales potential of Gilead's quad HIV drug.
Sometimes, the harder you throw a ball, the higher it bounces.
1 Biotech Punished by Hep-C Overreaction
Gilead slips, but hasn't fallen yet.
Gilead Sciences Shares Dropped: What You Need to Know
Is this meaningful? Or just another movement?
Gilead tries to prevent HIV infection … which could kill sales of its treatments for the infected.
These undervalued stocks have strong growth prospects.
Results 111 - 120 of 359 : Previous 8 9 10 11 12 13 14 15 16 Next
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK